CureVac Balance Sheet Health
Financial Health criteria checks 4/6
CureVac has a total shareholder equity of €376.5M and total debt of €0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are €556.8M and €180.3M respectively.
Key information
0%
Debt to equity ratio
€0
Debt
| Interest coverage ratio | n/a |
| Cash | €202.52m |
| Equity | €376.53m |
| Total liabilities | €180.30m |
| Total assets | €556.84m |
Recent financial health updates
We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05
We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Recent updates
CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 93% Above Its Share Price
Aug 03We're Hopeful That CureVac (NASDAQ:CVAC) Will Use Its Cash Wisely
Jul 05CureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both Pharmas
Jul 04Optimistic Investors Push CureVac N.V. (NASDAQ:CVAC) Shares Up 47% But Growth Is Lacking
Jun 01We Think CureVac (NASDAQ:CVAC) Needs To Drive Business Growth Carefully
Mar 20CureVac: No Momentum In Sight
Mar 08What Does The Future Hold For CureVac N.V. (NASDAQ:CVAC)? These Analysts Have Been Cutting Their Estimates
Aug 26CureVac N.V.'s (NASDAQ:CVAC) Intrinsic Value Is Potentially 89% Above Its Share Price
Jun 14Some Analysts Just Cut Their CureVac N.V. (NASDAQ:CVAC) Estimates
May 01Analysts Have Lowered Expectations For CureVac N.V. (NASDAQ:CVAC) After Its Latest Results
Apr 29An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 46% Undervalued
Jan 08CureVac BV reports Q2 results
Aug 18CureVac claims patent rights for Pfizer/BioNTech COVID-19 vaccine
Jul 05Will CureVac (NASDAQ:CVAC) Spend Its Cash Wisely?
May 29Analysts Are Betting On CureVac N.V. (NASDAQ:CVAC) With A Big Upgrade This Week
May 02A Look At The Intrinsic Value Of CureVac N.V. (NASDAQ:CVAC)
Oct 28CureVac: Wait For Concrete News Before Investing
Sep 01CureVac plunges as COVID-19 vaccine candidate indicates below par efficacy
Jun 16An Intrinsic Calculation For CureVac N.V. (NASDAQ:CVAC) Suggests It's 31% Undervalued
Jun 13CureVac tumbles on potential delay for European decision on its COVID-19 shot
Jun 08CureVac: The Moment Of Truth Arrives
Jun 01CureVac BV reports Q1 results
May 26CureVac Could Soon Join The Fight Against COVID-19
May 10CureVac N.V.'s (NASDAQ:CVAC) Has Found A Path To Profitability
May 02How Much Of CureVac N.V. (NASDAQ:CVAC) Do Insiders Own?
Mar 03Financial Position Analysis
Short Term Liabilities: CVAC's short term assets (€251.6M) exceed its short term liabilities (€110.0M).
Long Term Liabilities: CVAC's short term assets (€251.6M) exceed its long term liabilities (€70.3M).
Debt to Equity History and Analysis
Debt Level: CVAC is debt free.
Reducing Debt: CVAC currently has no debt however we can't compare to 5 years ago as we have no data for that period.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CVAC has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if CVAC has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.